Abstract
Purpose. Arildone, a novel lipophilic antiviral drug when evaluated in Clinical Trials showed limited skin absorption and antiviral efficacy. These studies were conducted to explain the apparent poor absorption characteristics and attempt to promote skin absorption by using Azone, a penetration enhancer.
Methods. Standard in vitro skin permeation methods using excised human skin were employed to characterise the absorption of Arildone. 14C-Arildone was used to estimate the distribution in skin layers by scintigraphic and autoradiographic procedures.
Results. The aqueous solubility and distribution constant values for Arildone were 2 µg ml−1 and 5 × 105 (isopropyl myristate/water), respectively. Absorption through full thickness skin or stratum corneum-viable epidermal membranes (diffusional resistant dermis removed), from a propylene glycol vehicle, was slow and the addition of Azone had no effect on the permeation rate. Distribution studies showed accumulation of Arildone in the stratum corneum. The concentration of Arildone in the viable epidermis was estimated from sectioning the skin and was found to be in sufficient amounts (400 µg cm−3) to have potential antiviral activity.
Conclusions. The apparent accumulation of Arildone in the stratum corneum suggested that the hydrophilic skin region presented the main barrier to permeation. Azone which affected the permeability of the stratum corneum was therefore not effective at enhancing Arildone absorption. Vehicles which readily permeate and enhance the transfer of lipophilic drugs from the stratum corneum into the viable epidermis were recommended.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
B.W. Barry. Dermatological Formulations: Percutaneous Absorption. Drugs and the Pharmaceutical Sciences, Volume 18, J. Swarbrick (Ed.) Marcel Dekker, New York, 1983.
J. Hadgraft. Penetration enhancers for percutaneous absorption. Pharm. Int. 5: 252–254 (1984).
R.B. Stoughton. Enhanced percutaneous penetration with 1-dodecylazacycloheptan-2-one. Arch. Dermatol. 118: 474–477 (1982).
S.L. Spruance, M. McKeough, K. Sugibayashi, F. Robertson, P. Gaede and D.S. Clark. Effect of Azone and propylene glycol on penetration of trifluorothymidine through skin and efficacy of different topical formulations against cutaneous herpes simplex virus infections in guinea pigs. Antimicrob. Agents Chemother. 26: 819–823 (1984).
P.K. Wotton, B. Møllgaard, J. Hadgraft and A. Hoelgaard. Vehicle effects on topical drug delivery III. Effect of Azone on the cutaneous permeation of metronidazole and propylene glycol. Int. J. Pharm. 24: 19–26 (1985).
N.V. Sheth, D.J. Freeman, W.I. Higuchi and S.L. Spruance. The influence of Azone, propylene glycol and polyethylene glycol on in vitro skin penetration of trifluorothymidine. Int. J. Pharm. 28: 201–209 (1986).
M. Goodman and B.W. Barry. Differential Scanning Calorimetry (DSC) of human stratum corneum. Effect of Azone. J. Pharm. Pharmacol. 37: Suppl. 80P (1985).
G.D. Diana, U.J. Salvador, E.S. Zalay, P.M. Carabateas, G.L. Williams, J.C. Collins and F. Pancic. Antiviral Activity of Some β-Diketones. 2. Aryloxy Alkyl Diketones. In Vitro Activity against Both RNA and DNA Viruses. J. Med. Chem. 20: 757–761 (1977).
D.P. Benziger, and J. Edelson. Disposition of Arildone, an Antiviral Agent, After Various Routes of Administration. Antimicrob. Agents Chemother. 22: 475–481 (1982).
J.A. Bosso, S.L. Spruance, and G. Wenerstrom. Tolerance and Percutaneous Absorption of Topically Applied Arildone. J. Clin. Pharmacol. 25: 95–99 (1985).
J.M. Douglas, Jr., F.N. Judson, M.L. Levin, J.A. Bosso, S.L. Spruance, J.M. Johnston, L. Corey, J.A. McMillan, L.B. Weiner, J.A. Frank, Jr. A placebo-controlled Trial of Topical 8% Arildone Cream Early in Recurrent Genital Herpes. Antimicrob. Agents Chemother. 29: 464–467 (1986).
E.J. Baker. Absorption of Drugs Across the Skin. Ph.D. Thesis, University of Nottingham, United Kingdom (1987).
A.M. Kligman and E. Christophers. Preparation of isolated sheets of human stratum corneum. Arch. Dermatol. 88: 702–705 (1963).
B.J. Poulsen, E. Young, V. Coquilla and M. Katz. Effect of topical vehicle composition on the in vitro release of fluocinolone acetonide and its acetate ester. J. Pharm. Sci. 57: 928–933 (1968).
J. Hadgraft. Structure activity relationships and percutaneous absorption. J. Control. Release. 15: 221–226 (1991).
G.L. Flynn, H. Dürrheim and W.I. Higuchi. Permeation of hairless mouse skin II: Membrane sectioning techniques and influence on alkanol permeabilities. J. Pharm. Sci. 70: 52–56 (1981).
R.L. Bronaugh and R.F. Stewart. Methods for in vitro percutaneous absorption studies III: Hydrophobic Compounds. J. Pharm. Sci. 73: 1255–1258 (1984).
R.L. Bronaugh and R.F. Stewart. Methods for In Vitro Percutaneous Absorption Studies V: Permeation through damaged skin. J. Pharm. Sci. 74: 1062–1066 (1985).
G.S. Hawkins and W.G. Reifenrath. Influence of skin source, penetration cell fluid and partition coefficient on in vitro skin penetration. J. Pharm. Sci. 75: 378–381 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baker, E.J., Hadgraft, J. In Vitro Percutaneous Absorption of Arildone, a Highly Lipophilic Drug, and the Apparent No-Effect of the Penetration Enhancer Azone in Excised Human Skin. Pharm Res 12, 993–997 (1995). https://doi.org/10.1023/A:1016202213317
Issue Date:
DOI: https://doi.org/10.1023/A:1016202213317